Core Insights - MaxCyte, Inc. has entered into a strategic platform license agreement with TG Therapeutics, allowing TG Therapeutics to utilize MaxCyte's Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes [1][2] - In exchange, MaxCyte will receive annual licensing fees and program-related revenue from TG Therapeutics [2] - TG Therapeutics is advancing its investigational allogeneic CD19 CAR T cell therapy, azer-cel, for autoimmune diseases, with plans to commence a Phase 1 trial in 2025 [3][4] Company Overview: MaxCyte - MaxCyte specializes in cell engineering technologies aimed at enhancing the discovery and commercialization of cell-based therapeutics [1] - The ExPERT™ platform is designed to support the growing cell therapy market, providing high transfection efficiency and scalability [4][5] - MaxCyte has over 25 years of experience in developing advanced platforms and technologies for cell therapy applications [5] Company Overview: TG Therapeutics - TG Therapeutics focuses on developing and commercializing novel treatments for B-cell diseases, including a pipeline of investigational medicines [6] - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis [6]

Core Insights - MaxCyte, Inc. will release its financial results for Q4 and full year 2024 on March 11, 2025, after U.S. market close [1] - A conference call to discuss these results will be held at 4:30 p.m. Eastern Time on the same day [1] Earnings Conference Call Details - Investors must register online to listen to the conference call, with a recommendation to register at least a day in advance [2] - A live and archived webcast of the conference call will be available on MaxCyte's investor relations website [2] - Company management will also participate in the 45th Annual TD Cowen Healthcare Conference on March 3, 2025, at 10:30 a.m. ET [2] About MaxCyte - MaxCyte focuses on cell engineering to enhance patient outcomes, with over 25 years of expertise in developing advanced platforms [3] - The ExPERT™ platform, utilizing Flow Electroporation® technology, supports the growing cell therapy market from discovery to commercialization [3] - The ExPERT product family includes four instruments and a range of proprietary processing assemblies and software protocols, backed by a strong intellectual property portfolio [3]

Core Viewpoint - MaxCyte, Inc. has announced the acquisition of SeQure Dx, enhancing its capabilities in cell and gene therapy development and commercialization [1][2] Group 1: Acquisition Details - MaxCyte acquired SeQure Dx for an initial cash consideration of $4.5 million, with potential contingent payments up to $2.5 million based on revenue targets [6] - SeQure Dx generated approximately $1.7 million in revenue and incurred a loss of about $6.5 million in 2024 [6] - The acquisition is expected to be accretive to MaxCyte's revenue growth and improve operational efficiencies [2][7] Group 2: Strategic Importance - The acquisition strengthens MaxCyte's service offerings for ex vivo and in vivo cell and gene therapy developers, providing innovative tools and services from early R&D to commercialization [2][3] - SeQure Dx specializes in precise editing confirmation and risk assessment for off-target effects, crucial for regulatory success in gene therapies [3][4] - The integration of SeQure Dx is aimed at enhancing safety and precision in cell therapies, aligning with MaxCyte's commitment to advancing cell engineering [4][5] Group 3: Company Background - SeQure Dx, co-founded by Dr. Keith Joung, emerged from stealth mode in late 2022 and offers a comprehensive portfolio of evaluation assays for off-target risk validation [4][10] - MaxCyte has over 25 years of experience in cell engineering, focusing on developing platforms that support the cell therapy market [9]

Core Viewpoint - MaxCyte, Inc. (MXCT) has received an upgrade to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates for MaxCyte indicate an improvement in the company's underlying business, likely leading to increased stock prices [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7][9]. - Only the top 5% of Zacks-covered stocks receive a 'Strong Buy' rating, indicating superior earnings estimate revisions [9][10]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2024, MaxCyte is expected to earn -$0.42 per share, reflecting a change of -13.5% from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for MaxCyte has increased by 0.8%, indicating positive sentiment among analysts [8].

Core Insights - MaxCyte, Inc. provided a preliminary update on its financial results for Q4 and the full year 2024, indicating a positive outlook for the cell therapy industry as it moves into 2025 [1][4]. Financial Performance - Total cash, cash equivalents, and investments as of December 31, 2024, are expected to be approximately $190 million, a decrease from $211 million on December 31, 2023, but higher than the updated guidance of $185 million [3]. - Core revenue for Q4 2024 is expected to be between $8.3 million and $8.5 million, compared to $7.2 million in Q4 2023 [6]. - Core revenue for the full year 2024 is expected to be between $32.2 million and $32.4 million, representing an 8 to 9% growth compared to $29.8 million for fiscal year 2023 [6]. Business Developments - The company increased the number of SPL customers by six in 2024 and supported the commercial launch of the first non-viral gene-edited cell therapy product approved by the FDA [4]. - MaxCyte's ExPERT™ platform is designed to support the expanding cell therapy market, facilitating the discovery, development, and commercialization of next-generation cell-based medicines [5].

Core Insights - MaxCyte, Inc. announced the retirement of Art Mandell from its Board of Directors effective December 31, 2024, after serving since 2006, contributing significantly to the company's growth and strategic direction [8][4][9] Company Overview - MaxCyte focuses on cell engineering, providing platform technologies to enhance the discovery, development, and commercialization of next-generation cell therapeutics [8] - The company has developed the ExPERT™ platform, which utilizes Flow Electroporation® technology, aimed at supporting the expanding cell therapy market [8][4] - The ExPERT family includes four instruments (ATx™, STx™, GTx™, VLx™), proprietary processing assemblies, and software protocols, backed by a strong intellectual property portfolio [8] Achievements - Under Mr. Mandell's leadership, MaxCyte achieved key milestones such as its initial public offering on the UK AIM exchange and US Nasdaq listing, the launch of the ExPERT™ platform, and signing 29 Strategic Platform Licenses with biotech companies [4][8] - The company also supported the first FDA-approved CRISPR edited non-viral cell therapy in the industry [4]

ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year. Over the past quarter-century, the company has remained steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technic ...

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.38%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.09, delivering a surprise of 35.71%.Over the last four quarters, the company has surpassed ...

Exhibit 99.1 MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, November 6, 2024 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cellengineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent Highlights ...

ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent Highlights Total revenue of $8.2 million in the third quarter of 2024, an increase of 2% over t ...